No Data
Vertex Pharmaceuticals B (02616.HK) has reached a global strategy partnership with Pharmalink for the development of Suglituzumab in the Middle East and Africa.
Galenghui November 21丨基石Pharmaceutical-B(02616.HK) announced that the company has reached a commercial strategic cooperation with Pharmalink Store- L.L.C - O.P.C ("Pharmalink"). Pharmalink is a well-known pharmaceutical company based in the United Arab Emirates. According to the license and commercialization agreement, Pharmalink will obtain the commercial rights of Shu Gel monoclonal antibody in the Middle East and North Africa, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Algeria, Tunisia.
CStone Pharmaceuticals Grants Commercial Rights of Tumor Drug for MENA Region to UAE Firm
Cornerstone Pharmaceutical (02616) announced the preclinical research data of CS2009.
King's Wealth Newsletter | Foundation Medicine (02616) announced that the company released the preclinical data of the heavyweight product CS2009 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC Annual Meeting). CS2009 is a three-specificity antibody targeting PD-1, CTLA-4, and VEGFA. Key highlights: 1) CS2009 is a three-specificity antibody targeting PD-1, CTLA-4, and VEGFA. 2) Preclinical data shows that CS2009 has significantly better anti-tumor activity than potential competitors. 3) CS2009 is expected to cover a wide range of tumor types.
Foundation Medicine-B (02616.HK) announced the CS2009 preclinical research data at the 2024 Annual Meeting of the Cancer Immunotherapy Society (SITC).
Galonti November 11th丨Cornerstone Pharmaceuticals-B (02616.HK) announced that the company unveiled the pipeline 2.0 blockbuster product CS2009's preclinical data at the 39th Society for Immunotherapy of Cancer (SITC Annual Meeting) Annual Meeting. CS2009 is a triple-specific antibody targeting PD-1, CTLA-4, and VEGFA. Key Highlights• CS2009 is a triple-specific antibody targeting PD-1, CTLA-4, and VEGFA. • Preclinical data show that CS2009 has significantly better anti-tumor activity than potential competitors.• CS2009 is expected to
Cornerstone Pharmaceuticals Group - B (02616) will announce the latest clinical data of CS5001 for lymphoma at the 66th American Society of Hematology (ASH) Annual Meeting.
Cornerstone Pharmaceuticals-B (02616) announced that the company will present at the 66th American Society of Hematology (ASH) Annual Meeting...
CStone Drug Gets UK Approval for First-Line Treatment of Non-Small Cell Lung Cancer
No Data
No Data